Editorial

Moving Towards the Future of Dyslipidemia Management

Authors: Asad Sheikh, MD, James L. Vacek, MD

Abstract

The practice of clinical cardiology faces the continuous struggle of minimizing recurrent cardiovascular events by risk factor modification. Current clinical guidelines assist the practicing physician in these efforts. Two of the primary risk factors are that of cholesterol and overall adverse dyslipidemic burden. Current guidelines are based primarily on low density lipoprotein (LDL) reduction, when in fact the spectra of cholesterol particles are much larger. The role of these particles is a topic of intense investigation although much more data needs to be produced to further clarify their significance in primary cardiovascular events.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–239.
 
2. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413–1419.
 
3. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998;81:26B–31B.